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expanded adoptively transferred antigen-specific CD8+ T 
cells in vivo. Importantly, the use of PD-L silenced DCs 
improved boosting and further expansion of ex vivo primed 
MiHA-specific CD8+ T cells in immunodeficient mice. In 
conclusion, adoptive transfer of ex vivo primed MiHA-
specific CD8+ T cells in combination with PD-L silenced 
DC vaccination, targeting MiHAs restricted to the hemat-
opoietic system, is an interesting approach to boost GVT 
immunity in allo-SCT patients and thereby prevent relapse.
Keywords Adoptive cell therapy · Dendritic cell · GVT · 
Leukemia · Minor histocompatibility antigen · PD-L
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Abstract Allogeneic stem cell transplantation (allo-SCT) 
can be a curative therapy for patients suffering from hema-
tological malignancies. The therapeutic efficacy is based 
on donor-derived CD8+ T cells that recognize minor his-
tocompatibility antigens (MiHAs) expressed by patient’s 
tumor cells. However, these responses are not always suf-
ficient, and persistence and recurrence of the malignant dis-
ease are often observed. Therefore, application of additive 
therapy targeting hematopoietic-restricted MiHAs is essen-
tial. Adoptive transfer of MiHA-specific CD8+ T cells in 
combination with dendritic cell (DC) vaccination could be 
a promising strategy. Though effects of DC vaccination in 
anti-cancer therapy have been demonstrated, improvement 
in DC vaccination therapy is needed, as clinical responses 
are limited. In this study, we investigated the potency of 
program death ligand (PD-L) 1 and 2 silenced DC vac-
cines for ex vivo priming and in vivo boosting of MiHA-
specific CD8+ T cell responses. Co-culturing CD8+ T cells 
with MiHA-loaded DCs resulted in priming and expansion 
of functional MiHA-specific CD8+ T cells from the naive 
repertoire, which was augmented upon silencing of PD-L1 
and PD-L2. Furthermore, DC vaccination supported and 
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PGE2  Prostaglandin E2
RFS  Relapse-free survival
Tem  Effector memory T
Tn  Naive T
TNF  Tumor necrosis factor
Introduction
Allogeneic stem cell transplantation (allo-SCT) can be a 
curative therapy for patients suffering from high-risk hema-
tological malignancies [1–3]. Donor-derived CD8+ T cells 
play an important role in the therapeutic effect of this treat-
ment, the so-called graft-versus-tumor (GVT) reaction. 
These CD8+ T cells can be directed against minor histo-
compatibility antigens (MiHAs) that are human leukocyte 
antigen (HLA)-bound peptides derived from polymorphic 
genes that differ between patient and donor [4, 5]. Impor-
tantly, a selective GVT response occurs when the expres-
sion of these MiHAs is restricted to hematopoietic tissues 
[6]. Previously, we showed that patients transplanted with 
a stem cell graft from a MiHA-mismatched donor (patient 
expressing the MiHA, whereas the donor does not) have an 
improved relapse-free survival (RFS) [7]. This RFS was 
especially increased in patients in whom MiHA-specific 
CD8+ T cells could be detected. However, these responses 
are infrequent, and persistence or recurrence of the malig-
nant disease is often observed. This emphasizes the need 
to further boost GVT-selective MiHA-specific CD8+ T cell 
responses in allo-SCT patients.
One of the current additive treatment options is donor 
lymphocyte infusion (DLI). However, this non-selected 
donor T cell product contains only a limited number of 
naive T cells recognizing hematopoietic-restricted MiHAs 
that are able to contribute a specific GVT effect. Moreover, 
T cells present in the DLI can also recognize polymorphic 
antigens expressed by healthy host tissues, thereby causing 
graft-versus-host disease (GVHD) [8, 9], the major cause 
of morbidity and mortality post-allo-SCT. Therefore, adop-
tive T cell therapy with purified and expanded donor CD8+ 
T cells selective for MiHAs restricted to the hematopoietic 
system could lead to a more efficacious GVT effect without 
promoting GVHD.
T cell responses can be initiated, supported and boosted 
by dendritic cells (DCs). These professional antigen-pre-
senting cells can activate T cells upon presentation of a 
peptide in concordance with co-stimulatory signals, which 
is dependent on the balance between co-inhibitory and co-
stimulatory interactions. Two of the co-inhibitory ligands 
involved in this process are program death ligand (PD-L) 1 
and PD-L2. We have shown previously that their receptor, 
program death (PD)-1, is highly expressed on MiHA-spe-
cific CD8+ T cells after allo-SCT, possibly due to chronic 
antigen exposure as observed in chronic viral infections 
[10]. This high PD-1 expression was involved in the func-
tional inhibition of MiHA-specific CD8+ T cells. Impor-
tantly, we demonstrated that interference with this path-
way resulted in enhanced expansion of MiHA-specific 
CD8+ T cells of allo-SCT patients in vitro [10–12]. Either 
by using blocking antibodies against PD-1 or PD-L1 [10] 
or by silencing the inhibitory ligands PD-L1 and PD-L2 on 
DCs, which results in more stimulatory DCs, we augmented 
the expansion of MiHA-specific CD8+ T cells of allo-
SCT patients in vitro. As PD-1/PD-L1 blocking antibodies 
early after allo-SCT might increase the risk of GVHD [13], 
adoptive transfer of tumor-reactive T cells in combination 
with DC vaccination would be a safer adjuvant therapeu-
tic approach early post-allo-SCT. These DCs can maintain 
and expand the adoptively transferred MiHA-specific CD8+ 
T cells, which will contribute to the reduction in the tumor 
load and generation of an immunological memory to control 
relapse. Though some clinical responses of DC vaccination 
in anti-cancer therapy have been demonstrated, improve-
ment in DC vaccination therapy is needed [14–19]. By 
augmenting the stimulatory capacity of DCs, via silencing 
of the co-inhibitory ligands PD-L1 and PD-L2, we aim to 
superiorly boost and augment adoptively transferred MiHA-
specific CD8+ T cell responses in vivo and thereby improve 
survival. In this study, we show that using monocyte-derived 
DCs, functional MiHA-specific CD8+ T cells can be primed 
and expanded in vitro, which is augmented by silencing the 
co-inhibitory ligands PD-L1 and PD-L2 on the DCs. More-
over, we demonstrate in immunodeficient mice that DC vac-
cination can boost the expansion of adoptively transferred 
MiHA-specific CD8+ T cells, in which PD-L silenced DCs 
show their superior stimulatory potential.
Materials and methods
Donor material and MiHA genotyping
Peripheral blood mononuclear cells (PBMCs) were isolated 
from HLA-A2 and HLA-B7 positive buffy coats (Sanquin 
Blood Supply Foundation, Nijmegen, the Netherlands) 
after written informed consent. PBMCs were genotyped 
for the MiHAs HA1 [20], HA2 [21], LRH1 [22] and ARH-
GDIB [23] with the KASPar assay system (KBioscience, 
Hoddesdon, UK), a fluorescence-based competitive allele-
specific PCR using non-labeled primers. Details of this 
method are available at http://www.kbioscience.co.uk.
siRNAs targeting PD-L1 and PD-L2
PD-L1 and PD-L2 siRNAs were kindly provided by dr. Anna 
Borodovsky from Alnylam Pharmaceuticals and produced 
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as described previously [12, 24]. The duplex sequences were 
as follows: PD-L1, 5′AGAccuuGAuAcuuucAAAdTsdT-3′ 
(sense), 5′-UUUGAAAGuAUcAAGGUCUdTsdT-3′ (anti-
sense); PD-L2, 5′-AuAAcAGccAGuuuGcAAAdTsdT-3′ 
(sense), 5′-UUUGcAAACUGGCUGUuAUdTsdT-3′ 
(anti-sense). As a negative control, a siRNA duplex for 
luciferase was used, with the sequence 5′-cuuAcGcu-
GAGuAcuucGAdTsdT-3′ (sense) and 5′-UCGAAGuA-
CUcAGCUcAGCGuAAGdTsdT-3′ (anti-sense). Small case 
represents 2′-O-methyl-modified residues.
DC culture and PD-L silencing
Monocytes were isolated from PBMCs via plastic adher-
ence in tissue culture flasks (Greiner Bio-One, Alphen a/d 
Rijn, the Netherlands). Intermediate DCs were generated 
by culturing monocytes in X-VIVO15 medium (Lonza, 
Verviers, Belgium) supplemented with 2 % human serum 
(HS; PAA laboratories, Pasching, Austria), 500 U/ml 
interleukin (IL)4 and 800 U/ml granulocyte macrophage 
colony-stimulating factor (GM-CSF, both Immunotools, 
Friesoythe, Germany). After 3 days, intermediate DCs 
were supplemented with fresh medium and cytokines or 
were transferred to 6-well plates and further cultured at 
0.5 × 106/ml X-VIVO15 supplemented with 2 % HS, 
500 U/ml IL4 and 800 U/ml GM-CSF. At day 7, matura-
tion was induced in X-VIVO15/2 % HS containing 5 ng/ml 
IL1ß, 15 ng/ml IL6, 20 ng/ml tumor necrosis factor (TNF)
α (all Immunotools) and 1 µg/ml prostaglandin E2 (PGE2) 
(Pharmacia and Upjohn, Bridgewater, NJ, USA). At day 9, 
mature DCs were harvested, phenotyped and used in exper-
iments. PD-L1 and PD-L2 were silenced using siRNAs and 
delivered via standard methods as described previously [11, 
12] (Roeven et al., Journal of Immunotherapy, accepted for 
publication). Previously, we showed that PD-L1/PD-L2 
siRNA silencing did not affect expression of the cell sur-
face markers CD14, CD80, CD83, CD86, CCR7, MHC-I 
and MHC-II [12].
Priming of MiHA-specific CD8+ T cells
Peripheral blood lymphocytes (PBLs), CD8+ T cells, naive 
or effector memory CD8+ T (Tn and Tem, respectively) 
cells were used in MiHA-specific CD8+ T cell priming 
experiments as indicated. CD8+ T cells were isolated using 
MACS microbeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufacturer’s guidelines. To 
isolate Tn or Tem cells, CD3+CD8+CD45RA+CCR7+ 
and CD3+CD8+CD45RA−CCR7− cells were sorted after 
CD8 MACS isolation using the FACS Altra (Beckman 
Coulter, Fullerton, CA, USA). Priming was performed by 
co-culturing PBLs, CD8+, Tn or Tem cells with mature 
PD-L silenced or control siRNA-treated DCs, loaded 
with 5 µM MiHA peptide. Cells were cultured for 7 days 
in IMDM/10 % HS at a T cell:DC ratio of 1:0.1. At day 2 
and 5, IL2 (50 U/ml, Chiron CA, USA) and IL15 (5 ng/ml, 
Immunotools) were added. At day 7, T cells were analyzed 
by flow cytometry and when indicated re-stimulated for an 
additional week.
Flow cytometry
Phenotype and maturation state of DCs were analyzed 
by staining with the following antibodies against PD-L1 
(clone MIH1), PD-L2 (clone MIH18, both from Becton–
Dickinson, Franklin Lakes, NJ, USA) and isotype control 
IgG1 (Dako). Cytomegalovirus (CMV), LRH1, HA1, HA2 
and ARHGDIB-specific CD8+ T cells were detected by 
staining cells with tetramers containing the corresponding 
peptide (CMV.B7: RPHERNGFTVL; LRH1.B7: TPN-
QRQNVC; HA1.A2: VLHDDLLEA; HA2.A2: YIGEV-
LVSV; ARHGDIB.B7: LPRACWREA). Tetramers were 
kindly provided by prof. Dr. Frederik Falkenburg (Depart-
ment of Hematology, Leiden University Medical Center, 
Leiden, the Netherlands). Cells were incubated with 0.15–
0.2 μg APC and PE labeled tetramer for 15 min at room 
temperature. Subsequently, cells were labeled with anti-
bodies against the surface markers: mouse CD45 (clone 
30-F11, Biolegend, San Diego, CA, USA), human CD45 
(clone J33, Beckman Coulter), CD8 (clone 3B5, Life Tech-
nologies, Grand Island, NY, USA), CD3 (clone UCHT1, 
Biolegend), CD45RA (clone 2H4LDH11LDB9, Beck-
man Coulter), CCR7 (clone 150503, R&D Systems) and 
CD28 (Biolegend) for 30 min at 4 °C. After washing with 
PBS/0.5 % bovine serum albumin (BSA; Sigma, St Louis, 
MO, USA), cells were resuspended in washing buffer con-
taining 1:5000 Sytox Blue (Life Technologies) to discrimi-
nate dead cells and analyzed using the Cyan-ADP 9 color 
analyzer or the Gallios (both Beckman Coulter). Analysis 
was performed using Summit (Dako) and Kaluza software 
(Beckman Coulter).
MiHA-specific CD8+ T cell functionality assay
Primed MiHA-specific CD8+ T cells were tested for their 
IFNγ production upon peptide rechallenge. Therefore, cells 
were restimulated overnight with MiHA peptide (5 µM) in 
the presence of brefeldin A (1 µg/ml, BD Biosciences). The 
following day, extracellular staining by MiHA tetramers 
and antibodies recognizing CD3 and CD8 was performed, 
followed by intracellular staining for IFNγ. For this, cells 
were resuspended in 4 % paraformaldehyde (PFA) and 
incubated for 10 min at RT. Then, cells were incubated in 
0.1 % saponin (Sigma) buffer containing 10 % fetal calf 
serum (Integro, the Netherlands) for 10 min at RT. This was 
followed by intracellular staining for anti-CD137 (clone 
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41BB, Biolegend) and anti-IFNγ (clone B27, BD Bio-
sciences) for 30 min at 4 °C after which cells were fixed in 
1 % PFA and measured on the Gallios flow cytometer.
Antigen-specific CD8+ T cell expansion in vivo by DC 
vaccination
NOD/SCID/IL2Rγnull (NSG) mice were originally pur-
chased from Jackson Laboratories, and housed and bred 
in the Radboud university medical center (Radboudumc) 
Central Animal Laboratory. Female NSG mice were used 
from 6 to 20 weeks of age. All animal experiments were 
approved by the Animal Experimental Committee of the 
Radboudumc and were conducted in accordance with insti-
tutional and national guidelines, permit number 10300.
Mice were i.v. injected with 10–15 × 106 (cultured) 
PBLs containing antigen-specific CD8+ T cells and weekly 
vaccinated with 0.25–0.5 × 106 peptide-loaded autologous 
control or PD-L silenced DCs (i.p.). To support antigen-
specific CD8+ T cells, 0.5 μg recombinant human IL15 
(Miltenyi, i.e., 2500 units) was administered i.p. every 
2–3 days when indicated. At indicated time points, mice 
were killed and organs were analyzed for presence of anti-
gen-specific CD8+ T cells by flow cytometry.
Statistical analysis
The data were analyzed using Graphpad Prism 4. Statis-
tical significance was analyzed using a Student’s t test or 
one-way analysis of variance (ANOVA) followed by a 
Bonferroni post hoc test as indicated in the figure legends. 
p < 0.05 was considered to be significant.
Results
Highly efficient priming and expansion of MiHA-specific 
CD8+ T cells by PD-L silenced DCs
Previously, we showed that PD-L silenced DCs augment 
expansion of MiHA-specific CD8+ effector memory cells 
from transplanted patients [11, 12]. To study the potency 
of PD-L silenced DCs in the expansion of MiHA-specific 
CD8+ T cells from the naive repertoire, in vitro priming 
experiments were performed using CD8+ T cells from 
MiHA-negative donors. These T cells were co-cultured 
with MiHA peptide-loaded HLA-A2+ or B7+ DCs, and 
weekly analyzed by flow cytometry. At day 7, we observed 
an average of 0.02 % MiHA-specific CD8+ T cells in the 
cultures (Fig. 1a–b; Table 1). Phenotypical analysis of these 
T cells showed high expression of the co-stimulatory mol-
ecule CD28 (Fig. 1c). In addition, the functionality of these 
T cells was determined by overnight peptide rechallenge 
followed by intracellular staining for IFNγ. Upon this anti-
gen-specific stimulation, we observed production of IFNγ, 
but only in cells expressing the activation marker CD137 
(Fig. 1d). Within this activated T cell population, 59 % of 
the cells produced IFNγ, indicating high functionality of 
the expanded MiHA-specific CD8+ T cells. Combined, this 
showed the feasibility of this method using DCs to ex vivo 
prime and generate highly functional MiHA-specific CD8+ 
T cells.
Next, we investigated whether PD-L silenced DCs 
would be more effective in priming MiHA-specific CD8+ T 
cells. Therefore, we co-cultured CD8+ T cells with peptide-
loaded control or PD-L silenced DCs. Though MiHA-spe-
cific CD8+ T cells could be expanded by control DCs, the 
use of PD-L silenced DCs strongly augmented the expan-
sion of MiHA-specific CD8+ T cells within 2 weeks of 
culture (Fig. 1e). This resulted in a tenfold increase in the 
absolute number of MiHA-specific CD8+ T cells (Fig. 1f). 
These data show the superior potency of PD-L silenced 
DCs in the priming and expansion of MiHA-specific CD8+ 
T cells from MiHA-negative donors.
To exclude that this observation could be attributed 
to the expansion of antigen-experienced MiHA-specific 
CD8+ effector memory T cells developed during preg-
nancy [25], both naive and effector memory CD8+ T cells 
were sorted from a MiHA− donor, after which they were 
co-cultured with MiHA peptide-loaded control or PD-L 
silenced DCs. Again, highly efficient MiHA-specific CD8+ 
T cell priming was observed, but only in co-cultures that 
started with naive T cells (Fig. 2a). In co-cultures contain-
ing effector memory T cells, no MiHA-specific CD8+ T 
cells could be expanded. Although MiHA-specific CD8+ 
T cells primed from the naive repertoire by control DCs 
could be expanded to 1.6 % in 2 weeks, the use of PD-L 
silenced DCs resulted in augmented numbers of MiHA-
specific CD8+ T cells (Fig. 2a). Notably, these cells 
expanded to more than 40 % of MiHA-specific CD8+ T 
Table 1  Primed MiHA-specific CD8+ T cells
a
 Percentage of total CD8+ T cells
Donor MiHA MiHA-specific 
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cells after 1 week of re-stimulation. Together, this resulted 
up to 20-fold increase in MiHA-specific CD8+ T cells after 
2 weeks of culture (Fig. 2b). These data show the superior 
potential of PD-L silenced DCs in the priming and expan-
sion of MiHA-specific CD8+ T cell responses from the 
naive repertoire.
Expansion of antigen-specific T cells by DC vaccination 
in NSG mice
To investigate the stimulatory capacity of PD-L silenced 
DCs on supporting and boosting adoptively transferred T 
cells in vivo, we generated a mouse model in which NSG 
mice were injected with PBLs containing antigen-experi-
enced CD8+ T cells. Subsequently, mice were vaccinated 
weekly with peptide-loaded DCs. These mice received 
no, one, two or three DC vaccinations at weekly inter-
vals, and mice were killed 1 week after their last vaccina-
tion. Mice receiving no DC vaccination were killed at the 
end of the experiment, similar to the group receiving three 
DC vaccines. Engraftment of the adoptively transferred 
human cells increased in time from 0.02 ± 0.09 × 106/
ml at week 1 to 8.7 ± 7.4 × 106 human cells/ml at week 
3 in peripheral blood (PB, mean ± SD, Fig. 3a). In addi-
tion, in spleen we observed an increase from 2.2 ± 1.3 
to 110 ± 58 × 106 human cells. This human engraftment 
reflected the increase in CD8+ T cell numbers in both PB 
and spleen (Fig. 3b). Notably, the DC vaccinations did not 
affect engraftment levels or consistency, as similar num-
bers were observed between mice receiving no or three DC 
vaccinations. Though in some mice receiving only one DC 
vaccination low numbers of CMV-specific CD8+ T cells 
could be detected, levels were generally below the detec-
tion limit (data not shown). With increasing engraftment of 
human cells in time, boosted CMV-specific CD8+ T cells 
could be clearly detected in mice receiving three DC vacci-
nations. In these mice, a CMV-specific CD8+ T cell popu-
lation was detected up to 0.75 % of the total CD8+ T cell 
Fig. 1  Priming of functional MiHA-specific CD8+ T cells is 
enhanced by PD-L silenced DCs. CD8+ T cells were co-cultured with 
MiHA peptide-loaded allogeneic DCs and analyzed at day 7 by flow 
cytometry for the presence of MiHA-specific CD8+ T cells. a Rep-
resentative FACS plot of two independent cultures. The numbers in 
the FACS plots represent the percentage of MiHA-specific CD8+ T 
cells within the total CD3+CD8+ T cell population. b Combined data 
of nine independent cultures. c Representative FACS plot of CD28 
expression (black) on MiHA-specific CD8+ T cells at day 7 of cul-
ture, isotype control in gray. The numbers in the FACS plots repre-
sent mean fluorescence intensity (MFI). One out of four independ-
ent cultures is shown. d Representative FACS plot of cultured cells 
at day 7, which were overnight re-stimulated with peptide followed 
by intracellular staining for IFNγ and CD137. The number in the 
FACS plots represents the percentage of IFNγ+ cells within CD137hi 
CD8+ T cells. e–f CD8+ T cells were cultured for two consecutive 
weeks with HA-1 peptide-loaded PD-L silenced or control DCs (rela-
tive expression: PD-L1 6 %, PD-L2 23 %), and analyzed at day 14 
by flow cytometry for the presence of MiHA-specific CD8+ T cells. 
FACS plot (e) and absolute cell numbers (f) of cultures with control 
or PD-L silenced DCs, n = 1
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compartment in both spleen and PB. The absolute CMV-
specific CD8+ T cells number in DC vaccinated mice was 
56 ± 66 × 103 in spleen and 6.0 ± 4.7 × 103/ml in PB 
(Mean ± SD, Fig. 3c–d), which already in these two organs 
was 31 times higher than the infused number of CMV-spe-
cific CD8+ T cells, showing robust expansion of antigen-
specific CD8+ T cells in vivo. In mice receiving no DC 
vaccination, CMV-specific CD8+ T cells were undetectable 
Fig. 2  MiHA-specific CD8+ T cell priming and expansion from 
the naive repertoire is augmented by PD-L silenced DCs. Naïve (N, 
CD45RA+CCR7+) and effector memory (EM, CD45RA−CCR7−) 
CD8+ T cells were sorted and cultured for two consecutive weeks 
with HA-1 peptide-loaded PD-L silenced or control DCs (rela-
tive expression: PD-L1 7 %, PD-L2 12 %). The percentage (a) and 
cumulative numbers (b) of HA-1-specific CD8+ T cells obtained after 
stimulation with PD-L silenced or control DCs
Fig. 3  CMV-specific CD8+ T cell expansion by DC vaccination in 
vivo. Peripheral blood lymphocytes containing 2000 CMV-specific 
CD8+ T cells were injected in NSG mice and stimulated with no 
(ctrl), one, two or three peptide-loaded (5 µM) DC vaccinations at 
weekly intervals. Mice were killed 7 days after their last DC vaccina-
tion or at the end of the experiment (ctrl). Peripheral blood and spleen 
were analyzed by flow cytometry for human CMV-specific CD8+ T 
cells. Engraftment of human cells (a) and CD8+ T cell (b). Statistical 
analysis was performed using one-way ANOVA followed by a Bon-
ferroni post hoc test. c Representative FACS plot of CMV-specific 
CD8+ T cells after three DC vaccinations. The numbers in the FACS 
plots represent the percentage of CMV-specific CD8+ T cells within 
the total CD3+CD8+ T cell population. d Percentage and absolute 
cell numbers of CMV-specific CD8+ T cells of mice non-vaccinated, 
or vaccinated three times. Statistical analysis was performed using a 
one-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001
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at time of analysis (day 21). These data demonstrate that 
this mouse model can be used to evaluate DC-mediated 
expansion of adoptively transferred antigen-specific CD8+ 
T cells in a humanized setting.
PD-L silenced DCs enhanced expansion of adoptively 
transferred MiHA-specific CD8+ T cell
To study the stimulatory potency of PD-L silenced DCs in 
vivo, we first confirmed the stability of the silencing under 
inflammatory conditions. For this, we co-cultured DCs in 
the presence of IFNγ. Additionally, as the mouse model 
includes IL15 injections to support the survival and expan-
sion of antigen-specific T cells, the effect of this low-dose 
IL15 was also investigated. For this, PD-L silenced DCs 
were generated, expressing only 5.4 % of PD-L1 and 1.4 % 
of PD-L2 compared to their control DCs (Supplementary 
Figure 1A). After 48 h of culture in the presence of IFNγ 
and/or IL15, flow cytometry analysis revealed no effects 
on expression of PD-L1 or PD-L2 on either PD-L silenced 
or control DCs (Supplementary Figure 1B). Conclud-
ing, silencing of PD-L on DCs results in a co-stimulatory 
phenotype, which is stably retained under inflammatory 
conditions.
Next, we addressed the potency of PD-L silenced DCs 
to superiorly boost the expansion of adoptively trans-
ferred MiHA-specific CD8+ T cells in vivo. Therefore, 
MiHA-primed PBLs were injected in NSG mice fol-
lowed by weekly vaccinations with either control or PD-L 
silenced DCs (Fig. 4a). After 3 weeks, mice were killed. 
We observed similar engraftment levels of human CD45+ 
and CD8+ T cells in mice vaccinated with control or 
PD-L silenced DCs (Supplementary Figure 2). During the 
experiment, no signs of GVHD were observed, as weights 
of the mice were stable and no differences in fur appear-
ance, activity or statue were noticed between control and 
PD-L silenced DCs (data not shown). Interestingly, while 
mice vaccinated with control DCs showed only low levels 
of MiHA-specific CD8+ T cells (0.06 ± 0.11 %), PD-L 
silenced DCs expanded the MiHA-specific CD8+ T cell 
numbers up to 1.5 % in PB (0.53 ± 0.60 %, p = 0.046, 
Fig. 4b–c). Also, in spleen this increase in MiHA-specific 
CD8+ T cells by PD-L silenced DCs was observed, though 
did not reach significance (0.09 ± 0.10 % in case of con-
trol DCs vs. 0.32 ± 0.32 % in case of PD-L silenced DCs, 
p = 0.058). Nevertheless, absolute numbers of MiHA-
specific CD8+ T cells were significantly augmented in 
mice vaccinated with PD-L silenced DCs, in both spleen 
and PB (83 ± 129 vs. 590 ± 440/ml in PB, p = 0.011; and 
1.1 × 104 ± 1.5 × 104 vs. 4.8 × 104 ± 4.0 × 104 in spleen, 
p = 0.031, Fig. 4b–c). This resulted in a 4- versus 17-fold 
expansion of the MiHA-specific CD8+ T cells in control 
DC- versus PD-L silenced DC-treated mice, respectively. 
Fig. 4  PD-L silenced DCs enhanced MiHA-specific CD8+ T cell 
expansion in vivo. a HA1-primed PBLs containing 2900 HA1-spe-
cific T cells were injected in NSG mice and vaccinated three times 
with control or PD-L silenced (relative expression: PD-L1 13.1 %, 
PD-L2 10.5 %) DCs at weekly intervals. Mice were killed at day 21, 
and peripheral blood and spleen were analyzed by flow cytometry for 
human HA-1-specific CD8+ T cells. b Representative FACS plot of 
HA-1-specific CD8+ T cells in spleen after control or PD-L silenced 
DC vaccinations. The numbers in the FACS plots represent the per-
centage of HA-1-specific CD8+ T cells within the CD3+CD8+ T cell 
population. c Percentages within CD8+ T cells, and absolute levels of 
HA-1-specific CD8+ T cells in peripheral blood and spleen. Each dot 
represents a single mouse, n = 6 mice per group. Statistical analysis 
was performed using a one-tailed Student’s t test
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This demonstrated that PD-L silenced DCs exhibit 
enhanced stimulatory capacity to boost the expansion of 
adoptively transferred MiHA-specific CD8+ T cells in vivo.
Discussion
Despite the curative potential of allo-SCT, many patients 
relapse. In previous studies, we have demonstrated that the 
frequencies of productive T cell responses in these patients 
are inadequate. This emphasizes the need for additive ther-
apy to improve GVT immunity and consequently overall 
survival of patients suffering from hematological malignan-
cies. To reduce the risk of GVHD, these additive therapies 
should exploit MiHA-specific CD8+ T cells recognizing 
antigens expressed solely by the hematopoietic system. By 
this, selective GVT immunity could be boosted without 
promoting GVHD.
Currently, additive T cell therapy can be given post-allo-
SCT as DLI. Yet, these non-selected donor lymphocytes 
contain only few tumor-reactive T cells, while a substantial 
percentage of T cells could contribute to the life-threaten-
ing complication GVHD. Ex vivo priming of donor lym-
phocytes would enrich the DLI for GVT-specific MiHA-
specific CD8+ T cells. Although priming of MiHA-specific 
CD8+ T cells can occur during pregnancy [25], the MiHA-
specific CD8+ T cell responses in our assays most likely 
emerged from the naive T cell repertoire, as confirmed by 
the absence of MiHA-specific CD8+ T cell responses in 
case effector memory T cells, were used as starting mate-
rial. Notably, the extent of the ex vivo primed MiHA-spe-
cific CD8+ T cell responses varied between donors, prob-
ably due to variation in precursor frequencies between 
donors and different MiHAs [26, 27]. In this manuscript, 
we are the first to demonstrate that the use of PD-L silenced 
DCs in these ex vivo cultures greatly enhanced the priming 
and expansion of MiHA-specific CD8+ T cell responses. 
Notably, we recently demonstrated that ex vivo priming of 
the MiHA-specific CD8+ T cells for adoptive T cell trans-
fer could be further improved by retaining these cells in an 
early memory state using a selective Akt-inhibitor during 
ex vivo culture [28].
DC vaccination is a strong tool to boost adoptively trans-
ferred MiHA-specific CD8+ T cells. To improve the activa-
tion and expansion of these tumor-reactive T cells by DC-
based stimulation, one can interfere with the co-inhibitory 
PD-1/PD-L pathway. Though recent papers showed clinical 
effects of PD-1 blockade in solid tumors and after autolo-
gous stem cell transplantation without causing severe side 
effects [29–31], speculations have been made on the risk 
of these blocking antibodies on GVHD. Addition of PD-1/
PD-L1 blocking antibodies to the activated immune system 
early after allo-SCT could further release the brake on all 
activated T cells, resulting in the induction and aggravation 
of GVHD. Therefore, we believe that PD-L silenced DCs 
are a safer way to interfere with the PD-1/PD-L pathway 
in the allo-SCT setting, and thereby potently augment the 
activation and expansion of MiHA-specific CD8+ T cells. 
The use of DC vaccinations to boost tumor-reactive T cells 
is a safe and feasible application as shown in several DC 
vaccination trials in cancer patients [32]. Applying adoptive 
transfer of hematopoietic-restricted MiHA-specific CD8+ 
T cells in combination with potent PD-L silenced DC vac-
cines could augment GVT immunity and thereby prevent 
relapse and improve survival.
We previously showed the potential of PD-L silenced 
DCs in the expansion of MiHA-specific CD8+ effector 
memory T cells in vitro [11, 12]. In this paper, we are the 
first to demonstrate that PD-L silenced DCs are also supe-
rior in boosting antigen-specific CD8+ T cells in vivo. 
Moreover, in addition to our superior expansion, Pen et al. 
[33] recently showed improved cytokine production of T 
cells upon interference with the PD-1/PD-L1 pathway. This 
was also shown by Lesterhuis et al. [34], who demonstrated 
that upon down-regulation of PD-L1 and PD-L2 expression 
on DCs by platinum-based chemotherapeutics, antigen-spe-
cific T cells show enhanced proliferation and Th1 cytokine 
secretion. In addition, DNA vaccination of soluble PD-1, 
which interfered with the natural PD-1/PD-L1 interaction, 
resulted in an increased functionality and antitumor effect 
in mice [35]. More promisingly, Ge et al. [36] showed that 
the use of a PD-L1 blocking antibody during ex vivo prim-
ing of antigen-specific T cells and subsequent DC vacci-
nation resulted in a better cytokine production and expan-
sion of these T cells in vitro, and an improved anti-tumor 
effect in vivo. All together, these observations illustrate 
the potency of PD-L silenced DCs with adoptive transfer 
of MiHA-specific CD8+ T cells, which should be further 
explored for improving an antitumor effect in a relevant 
tumor therapy model. However, first a robust and appro-
priate isolation method to purify ex vivo primed MiHA-
specific CD8+ T cells before adoptive transfer into tumor-
bearing mice should be set up. This could be performed by 
the Streptamer technique obtaining viable MiHA-specific 
CD8+ T cells for adoptive immunotherapy [37].
Our current data illustrate a novel additive value of our 
approach in relation to previous reports. This therapeutic 
strategy would especially be attractive for clinical explora-
tion in patients who lack productive tumor-reactive T cell 
responses. The combination of adoptive transfer of ex vivo 
primed MiHA-specific CD8+ T cells with PD-L silenced 
DCs vaccines targeting hematopoietic-restricted MiHAs 
would greatly contribute to better GVT immunity with-
out inducing detrimental GVHD. This preemptive therapy 
could prevent relapse and thereby improve survival in allo-
SCT patients. Furthermore, our strategy could be broadly 
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exploited toward tumor-antigen or virus-specific CD8+ T 
cells in cancer and viral infections.
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